--- a
+++ b/clusters/orderedclusters/centers.txt
@@ -0,0 +1,300 @@
+Cluster 0: patients prior study eligible disease patient history treatment days registration
+Cluster 1: zubrod performance status patients registration days prior criteria step study
+Cluster 2: interstitial lung pneumonitis disease history pulmonary patients detection known symptomatic
+Cluster 3: monitoring comply safety opinion investigator able requirements eligible study patients
+Cluster 4: physical examination history registration days complete prior prestudy obtained patients
+Cluster 5: autoimmune disease systemic syndrome replacement history patients sclerosis treatment arthritis
+Cluster 6: composition compounds similar attributed chemical allergic reactions biologic used agents
+Cluster 7: compounds composition chemical similar attributed allergic reactions biologic history mln
+Cluster 8: olaparib chemical composition compounds attributed reactions similar allergic biologic cediranib
+Cluster 9: mother breastfeeding discontinued treated pregnant excluded women study vx mln
+Cluster 10: pregnant breastfeeding women excluded study discontinued treatment drug dose refrain
+Cluster 11: olaparib mother breastfeeding discontinued cediranib treated pregnant excluded women study
+Cluster 12: solid marrow tumors bone involvement known peripheral count anc patients
+Cluster 13: transplantation organ solid received allogeneic prior eligible patients marrow bone
+Cluster 14: marrow bone peripheral blood blasts biopsy aspirate patients performed involvement
+Cluster 15: standard survival prolong therapy progressed histologically tumors solid shown exist
+Cluster 16: tumors verification patients original elevations relapse fetoprotein beta hcg intrinsic
+Cluster 17: consent informed signed sign dated form written patient institutional guidelines
+Cluster 18: informed federal nature accordance guidelines sign written consent investigational institutional
+Cluster 19: guardians legal parents sign written informed consent patients assent according
+Cluster 20: representatives assent parents legally authorized according appropriate guidelines sign written
+Cluster 21: permitting authorization release personal information health signed approved informed consent
+Cluster 22: hcv hepatitis hbv virus infection cleared known chronic patients eligible
+Cluster 23: hepatitis antibody positive antigen hcv surface virus negative hbsag core
+Cluster 24: hepatitis known infection active virus chronic hiv viral patients immunodeficiency
+Cluster 25: transaminase aminotransferase uln serum ast glutamic alt liver sgot sgpt
+Cluster 26: transaminase aminotransferase serum sgpt glutamic sgot glutamate pyruvate oxaloacetic alt
+Cluster 27: sgpt alt uln purpose alanine transaminase glutamate pyruvate aminotransferase serum
+Cluster 28: transaminase serum aminotransferase sgot glutamic oxaloacetic ast uln aspartate sgpt
+Cluster 29: score lansky years karnofsky performance age patients status paralysis ambulatory
+Cluster 30: karnofsky performance status days step registration prior score sequencing ecog
+Cluster 31: help occasional care karnofsky able performance status patient patients kps
+Cluster 32: age years score walk wheelchair ambulatory assessing performance lansky patients
+Cluster 33: years age lansky performance ecog karnofsky scores cooperative eastern corresponding
+Cluster 34: years age enrollment patients time performance scale months lansky study
+Cluster 35: acquisition muga ejection fraction echocardiogram left gated ventricular multi scan
+Cluster 36: fraction echocardiogram shortening ejection radionuclide angiogram gated cardiac echo study
+Cluster 37: left fraction ejection ventricular lvef normal institutional function indicated heart
+Cluster 38: lln echo lower left echocardiogram ejection ventricular fraction institutional limit
+Cluster 39: understand document willingness ability written sign informed consent able guardian
+Cluster 40: provide informed consent written able willing ability inability patients unable
+Cluster 41: lar representative legally authorized understand document willingness ability sign written
+Cluster 42: limits normal institutional creatinine upper bilirubin days uln registration serum
+Cluster 43: iuln bilirubin total upper registration institutional limit normal days prior
+Cluster 44: bilirubin upper normal limit total uln institutional times days prior
+Cluster 45: conjugated sum unconjugated age bilirubin uln upper limit normal subprotocols
+Cluster 46: limits bilirubin normal total institutional uln upper gilberts direct registration
+Cluster 47: creatinine uln serum institutional times obtained grade prior days randomization
+Cluster 48: lln calcium serum magnesium potassium lower phosphorus limit normal delaying
+Cluster 49: age bilirubin total upper uln limit normal direct times institution
+Cluster 50: bilirubin uln total gilbert serum known level upper normal enrolled
+Cluster 51: bilirubin gilberts uln total normal upper syndrome limit institutional unless
+Cluster 52: gilbert bilirubin total uln syndrome upper limit normal exception institutional
+Cluster 53: bilirubin total upper institutional normal limit direct range sequencing allowed
+Cluster 54: vessels invading encasing major blood tumor subject contact indicate participant
+Cluster 55: endotracheal endobronchial tumor evidence invading tract gi esophagus anus rectum
+Cluster 56: cavitating radiographic pulmonary lesion evidence subject participant extended extensive extent
+Cluster 57: institutions identity process ensure board approval order open date entered
+Cluster 58: identity process ensure board approval order open entered date institution
+Cluster 59: weeks entering recovered adverse events earlier administered nitrosoureas mitomycin agents
+Cluster 60: radiotherapy weeks prior chemotherapy patients therapy entering study mitomycin nitrosoureas
+Cluster 61: grade alopecia toxicities recovered prior related adverse toxicity therapy patients
+Cluster 62: aminotransferase alt ast alanine aspartate uln iuln institutional days registration
+Cluster 63: aminotransferase aspartate ast alanine upper alt normal limit uln institutional
+Cluster 64: ast uln alt performed aminotransferase instead registration value lab practice
+Cluster 65: upper limit normal creatinine uln institutional ast serum prothrombin alt
+Cluster 66: corticosteroids decreasing stable corticosteroid dose receiving days prior mri patients
+Cluster 67: corticosteroid dose modify corticosteroids days elapsed immune decreasing stable related
+Cluster 68: nodal lesions mm measured measurable axis short longest recorded accurately
+Cluster 69: measurable neuroblastoma lesions disease detected fluid mibg bone collections gallium
+Cluster 70: dimension mm ct diameter lesion spiral longest recorded measurable accurately
+Cluster 71: childbearing pregnancy test potential negative women serum registration days prior
+Cluster 72: bearing pregnancy test child negative females potential urine serum prior
+Cluster 73: female pregnancy childbearing potential pregnant test negative patients result urine
+Cluster 74: nursing childbearing pregnancy test pregnant negative women potential required registration
+Cluster 75: nursing pregnant women mothers patients excluded unwilling pregnancy step birth
+Cluster 76: platelets mcl platelet transfusion transfusions requiring plt weeks equal cells
+Cluster 77: platelet independent transfusion transfusions mm count enrollment defined receiving involvement
+Cluster 78: ul platelet count transfusion cells independent cd unsupported platelets days
+Cluster 79: ul platelets mcl untransfused unsupported cells sequencing biopsy treatment tumor
+Cluster 80: monoclonal hypersensitivity antibody reaction severe history ineligible grade exclusion stratum
+Cluster 81: dmso immediate chemically dimethyl sulfoxide excipients idiosyncrasy delayed trametinib hypersensitivity
+Cluster 82: humanized anaphylactic proteins chimeric antibodies fusion allergic reactions severe hypersensitivity
+Cluster 83: immunotherapies activating conjugates brentuximab prior vedotin restrictions checkpoint purposes monoclonal
+Cluster 84: myelodysplastic mds aml leukemia myeloid syndrome acute suggestive features smear
+Cluster 85: syndrome fanconi anemia bloom telangiectasia shwachman kostmann ataxia known genetic
+Cluster 86: transfusions hematologic evaluable toxicity provided red known platelet meet refractory
+Cluster 87: chinese hamster ovary recombinant products hypersensitivity antibodies cell human known
+Cluster 88: syndrome patients gilberts known excluded trisomy necrolysis stevens history epidermal
+Cluster 89: protein urine urinalysis hour mg dipstick proteinuria screened obtained electrophoresis
+Cluster 90: protein urine ratio upc creatinine upcr proteinuria hour dipstick collection
+Cluster 91: expectancy life greater months weeks appropriate patient estimated sequencing equal
+Cluster 92: expectancy life weeks patients estimated participants physician years procurement year
+Cluster 93: pregnant partner participating inform suspect immediately woman physician treating study
+Cluster 94: chemotherapy randomization surgery adjuvant administered days breast neoadjuvant cancer interval
+Cluster 95: cancer breast invasive situ skin years malignancy carcinoma non melanoma
+Cluster 96: malignancy melanotic cancer specific cervix situ skin carcinoma exceptions prior
+Cluster 97: received prior patients treatment days therapy study chemotherapy dose previously
+Cluster 98: inhibitor parp mek prior treatment kinase braf patients received therapy
+Cluster 99: rankl denosumab atezolizumab discontinue treatment inhibitor requiring patients kappa require
+Cluster 100: hsp inhibitor prior therapy received treatment patients zubrod expiratory experiences
+Cluster 101: abdominal abscess intra perforation gastrointestinal fistula months obstruction history diverticulitis
+Cluster 102: fistula gastrointestinal perforation history abdominal months repaired postoperative starting surgically
+Cluster 103: qtc prolong drugs alternatives interval receiving pointes torsades cause alternative
+Cluster 104: qt qtc interval milliseconds corrected torsades pointes prolongation long congenital
+Cluster 105: qt syndrome long congenital qtc family history ecg corrected msec
+Cluster 106: qt interval qtc corrected msec qtcf fridericia formula electrocardiogram ms
+Cluster 107: cardiac heart york association iii resulting activity iv new physical
+Cluster 108: heart myocardial infarction failure months congestive angina history york association
+Cluster 109: stage iv iii disease patients cancer ii carcinoma ovarian diagnosis
+Cluster 110: time measurements obtain prothrombin ptt thromboplastin pt normalized inr neurologic
+Cluster 111: thromboplastin partial time aptt ptt activated uln normal upper limit
+Cluster 112: inr normalized international ratio time thromboplastin prothrombin ptt partial uln
+Cluster 113: pt anticoagulant ptt time thromboplastin anticoagulants intended therapeutic range partial
+Cluster 114: hodgkin expansion lymphoma cohort participants enrollment weeks prior dl serum
+Cluster 115: albumin dl serum days registration patients prior hypersensitivity mg inclusion
+Cluster 116: phosphatase alkaline uln involvement iuln days liver prior registration bone
+Cluster 117: creatinine mg dl serum registration iuln days prior umol level
+Cluster 118: area surface body bsa enrollment patients time study mg level
+Cluster 119: bilirubin mg dl total direct serum gilbert patient syndrome registration
+Cluster 120: requiring hypothyroidism autoimmune mellitus recur trigger psoriasis diabetes expected vitiligo
+Cluster 121: glucose fasting mg dl blood diabetes serum mellitus age random
+Cluster 122: bun urea nitrogen blood mg dl chloride bicarbonate glucose phosphatase
+Cluster 123: transplant stem cell allogeneic autologous prior graft host patients transplantation
+Cluster 124: tacrolimus cyclosporine transplant prevent host post versus graft marrow trial
+Cluster 125: creatinine clearance gault min formula cockcroft ml calculated hour serum
+Cluster 126: creatinine clearance min ml calculated serum measured uln crcl obtained
+Cluster 127: creatinine institutional normal levels clearance min ml upper limit patients
+Cluster 128: calc creatinine calculated min clearance ml uln upper mg normal
+Cluster 129: gfr glomerular filtration rate min ml creatinine radioisotope clearance estimated
+Cluster 130: creatinine gault cockcroft clearance min ml equation using calculated formula
+Cluster 131: gp inhibitors glycoprotein inducers bcrp strong binding member cypa adenosine
+Cluster 132: cytochrome subfamily cypa family polypeptide strong inhibitors inducers cypc medications
+Cluster 133: strong cypc miscellaneous inducers cypa inhibitors wort st antibiotics agents
+Cluster 134: cypa inducers strong inhibitors medications drugs use substances concomitant moderate
+Cluster 135: cypc strong inducers inhibitors cyp cytochrome week preceding cypa alternative
+Cluster 136: inhibitors azacitidine decitabine deacetylase histone hydroxyurea interferon tyrosine hematopoietic thalidomide
+Cluster 137: swallow able pills absorb medication patients inability drug explained experiencing
+Cluster 138: oral swallow medications ability medication retain able absorption gastrointestinal unable
+Cluster 139: retain stomach malabsorption bowels alter medication abnormalities swallow absorption major
+Cluster 140: bowel gastrointestinal vomiting absorption nausea resection disease significantly inflammatory diseases
+Cluster 141: fast mln maintain oral hour hours medication administration required bowel
+Cluster 142: obstruction bowel signs symptoms starting drugs history month current study
+Cluster 143: state curative survival quality therapy prolong current proven life acceptable
+Cluster 144: oximetry pulse dyspnea rest air room exercise evidence intolerance breathing
+Cluster 145: rvo retinal occlusion vein history evidence current risk csr intraocular
+Cluster 146: dependency tpn hydration nutrition parenteral iv total intravenous current participants
+Cluster 147: history coronary heart evidence cardiac controlled mmhg current defined subjects
+Cluster 148: overlap fields radiation result pelvis therapy neck head irradiation previous
+Cluster 149: overlap fields region result radiotherapy radiation cancer therapy prior study
+Cluster 150: dipg stratum progressed progressive recurrent non patients irradiation refractory enrollment
+Cluster 151: eiaed epileptic drugs inducing anti enzyme taking patients previously enrolled
+Cluster 152: aallb aall apecb open enrolled enrollment patients classification project sample
+Cluster 153: anticonvulsants seizure inducing enzyme disorder controlled enrolled seizures patients non
+Cluster 154: seizure disorder uncontrolled history patients seizures active generalized months medication
+Cluster 155: metastatic disease locally advanced patients evidence unresectable prior cancer definitive
+Cluster 156: histologically confirmed cytologically cancer diagnosis metastatic patients proven unresectable cell
+Cluster 157: ain anal stain intraepithelial neoplasia hsil proven biopsy cyclin junction
+Cluster 158: higher neuropathy grade peripheral terminology common ctcae events adverse step
+Cluster 159: sensory motor neuropathy grade ctcae peripheral terminology common equal events
+Cluster 160: neuropathy grade peripheral greater patients severity exceeds registration sensory permitted
+Cluster 161: myelosuppressive days dose enrollment prior chemotherapy agent immunomodulatory elapsed nitrosourea
+Cluster 162: days events adverse infusion growth known agent elapsed occurring extended
+Cluster 163: myelosuppressive weeks nitrosourea anticancer received chemotherapy study prior dose known
+Cluster 164: step registration prior weeks mcl induction screening treatment optional pre
+Cluster 165: pre criteria registration eligibility inclusion step experiences experiencing experimental expert
+Cluster 166: eligibility criteria step randomization registration induction meet preregistration screening operative
+Cluster 167: neutrophil absolute count mm microliters cells randomization enrollment weeks days
+Cluster 168: platelet count mm days registration randomization prior mcl obtained ml
+Cluster 169: absolute neutrophil mcl count growth hematopoietic factors days prior ul
+Cluster 170: leukocytes mcl mm ul lower registration equal days initiation obtained
+Cluster 171: granulocytes ul anc cells mcl absolute extending explained experiencing experimental
+Cluster 172: peripheral anc neutrophil absolute mm count zubrod exposed experimental expert
+Cluster 173: absolute neutrophil count ul anc peripheral unsupported cells lymphocyte weeks
+Cluster 174: anc neutrophil absolute count mcl registration days prior obtained equal
+Cluster 175: white wbc blood ul count cell cells randomization prior obtained
+Cluster 176: anc neutrophil absolute mm count cells days registration prior obtained
+Cluster 177: cells platelets mm days prior registration obtained entry study experiencing
+Cluster 178: brain metastases treated patients stable prior treatment mri imaging untreated
+Cluster 179: corticosteroids brain anticonvulsants inducing enzyme subjects weeks stable metastases month
+Cluster 180: alchemist screen alliance registered trial randomization prior patients express expressing
+Cluster 181: cns nervous central metastases involvement patients disease brain lumbar puncture
+Cluster 182: brain metastases carcinomatous meningitis remained stable trial patients clinical metastatic
+Cluster 183: brain metastases trial excluded clinical known patients participants described trials
+Cluster 184: contraceptive measures reproductive pregnancy effective bilateral potential use time celibacy
+Cluster 185: study agree contraception use male pregnant potential dose effective method
+Cluster 186: accepted males abstain sexually intercourse effective advised sexual contraception strongly
+Cluster 187: females method agreed males contraceptive reproductive effective participate unless menarchal
+Cluster 188: reproductive contraceptive sexually effective method agreed duration potential use participation
+Cluster 189: infection exhibiting bacterial fungal signs despite improvement antibiotics symptoms appropriate
+Cluster 190: signs symptoms cycle infection day weeks prior tuberculosis clinical active
+Cluster 191: infection active requiring systemic antibiotics severe patients therapy fungal septicemia
+Cluster 192: cancer adequately treated surveillance cell program patient localized followed cervical
+Cluster 193: carcinoma cell squamous skin basal situ malignancies treated malignancy years
+Cluster 194: cancer adequately treated cell basal patient squamous free situ skin
+Cluster 195: cancers skin patient thyroid advanced known active basal screening squamous
+Cluster 196: laboratory clia certified mutation braf improvement clinical amendments approved mutations
+Cluster 197: choice apecsc actionable match assignment given molecular analysis mutation presence
+Cluster 198: egfr exon tki tm mutation generation erlotinib deletion treatment testing
+Cluster 199: return enrolling institution follow willing alliance willingness monitoring active phase
+Cluster 200: permit circumstances follow completion required study travel issue instance patients
+Cluster 201: permits psychological general follow health ability completion requirements required study
+Cluster 202: sequencing antiretroviral combination immunodeficiency ineligible hiv biopsy virus human positive
+Cluster 203: immunodeficiency hiv virus human known positive infection patients excluded individuals
+Cluster 204: antiretroviral combination hiv ineligible immunodeficiency positive human virus therapy patients
+Cluster 205: hiv licensed assay record approved documentation test rapid western blot
+Cluster 206: immunocompromised hiv positive immunodeficiency virus human known corticosteroids related patients
+Cluster 207: hiv retroviral positive opportunistic virus haart immunodeficiency human cd regimen
+Cluster 208: hiv cd immunodeficiency cluster differentiation positive virus human antiretroviral count
+Cluster 209: medications systemic adrenocortical anti tnf mineralocorticoids azathioprine orthostatic fludrocortisone dose
+Cluster 210: anthracycline intravesical therapy prior excluded systemic patients muscle previous urothelial
+Cluster 211: chemotherapy cancer different allowable prior systemic note study egf current
+Cluster 212: radiation therapy prior chemotherapy received weeks patients pelvic elapsed treatment
+Cluster 213: edition ajcc committee joint th american cancer stage staging nsclc
+Cluster 214: therapy prior chemotherapy cancer systemic patients hormonal treatment anti radiation
+Cluster 215: registration therapy days prior radiation treatment investigational immunotherapy chemotherapy mitomycin
+Cluster 216: chemotherapy prior neoadjuvant patients received therapy treatment surgery radiation adjuvant
+Cluster 217: illness uncontrolled compliance social situations psychiatric intercurrent pectoris requirements arrhythmia
+Cluster 218: bp mmhg pressure blood antihypertensive diastolic systolic hypertension medications controlled
+Cluster 219: pressure blood mmhg hypertension systolic diastolic hypertensive uncontrolled controlled hg
+Cluster 220: triglyceride mg dl level fasting serum applicable mmol gsk nf
+Cluster 221: cholesterol mg dl level serum fasting mmol total draw gsk
+Cluster 222: fasting triglycerides mg dl equal cholesterol mmol lowering lipid values
+Cluster 223: mmol dl normalize mg despite intervention levels calcium hemoglobin adjusted
+Cluster 224: mg years age dl males creatinine females serum maximum min
+Cluster 225: mg dl years male female age creatinine gender radioisotope gfr
+Cluster 226: male female years creatinine age gender follows serum based radioisotope
+Cluster 227: maximum creatinine mg dl male age serum female years gender
+Cluster 228: transfusion hemoglobin dl days blood past enrollment prior administration preceding
+Cluster 229: hemoglobin dl transfused level weeks unsupported hg mg randomization criterion
+Cluster 230: platelets mm prior weeks days equivalent cell randomization ctcae enrollment
+Cluster 231: platelets mcl registration days prior obtained equal administration start step
+Cluster 232: hemoglobin dl hgb achieve intervention transfusion acceptable note use days
+Cluster 233: transfusions hemoglobin rbc dl red receive blood cell requiring involvement
+Cluster 234: step randomization ii prior days dl bilirubin mg cells mm
+Cluster 235: hemoglobin dl days registration prior randomization obtained step transfusions weeks
+Cluster 236: phase ii arms randomized portion patients criteria registration weeks prior
+Cluster 237: hbac glycosylated hemoglobin ac hb measurement equal registration days prior
+Cluster 238: hgb hemoglobin dl obtained transfusions registration days prior allowed procurement
+Cluster 239: cbc differential obtained blood count registration days complete step prior
+Cluster 240: corticosteroids steroids systemic prednisone mg inhaled immunosuppressive topical daily doses
+Cluster 241: complications resolved related infectious medical significant induction consolidation therapy cycle
+Cluster 242: ischemic revascularization artery event procedures including fibrillation ventricular cerebrovascular attack
+Cluster 243: significant unrelated organ dysfunction infections hepatic results interfere systemic procedures
+Cluster 244: fda food nci institute met national studies requirements human administration
+Cluster 245: adverse events common terminology ctcae grade criteria version alopecia prior
+Cluster 246: ctcae grade alopecia nci version institute terminology national unresolved common
+Cluster 247: pd anti prior therapy treatment agents patients ctla antibody progression
+Cluster 248: anti pd antibody ctla programmed death cell targeting lymphocyte cytotoxic
+Cluster 249: consent mandatory provide specific study entry informed tissue submission including
+Cluster 250: specific informed consent provide study registration signed representative prior legally
+Cluster 251: specific study provide informed consent entry patient prior representative legally
+Cluster 252: platelets microliters plt dependent study day transfusion dose weeks treatment
+Cluster 253: months teaspoon dose hemoptysis red treatment study indicative bleeding hemorrhage
+Cluster 254: half lives whichever dose shorter days investigational minimum preceding study
+Cluster 255: wound healing fracture ulcer non bone cabozantinib dose surgeries history
+Cluster 256: live vaccine attenuated influenza vaccines vaccination flu seasonal dose study
+Cluster 257: ppi pump proton inhibitor receiving dose study concomitant stop using
+Cluster 258: consecutive female childbearing months mature naturally potential postmenopausal menses bilateral
+Cluster 259: fathering willing childbearing birth control child potential medically form treated
+Cluster 260: consecutive undergone childbearing potential months orientation naturally meets sexual ligation
+Cluster 261: fcbp pregnancy lenalidomide agree effective method childbearing consecutive days commit
+Cluster 262: capsules swallow able patients tube nasogastric broken crushed inability tablets
+Cluster 263: uncontrolled infection eligible patients active patient step subprotocols excluded general
+Cluster 264: intact capsules swallow able patients subprotocol subprotocols assigned general tablets
+Cluster 265: tablets swallow able unable intact patients subject ability eligible chewed
+Cluster 266: karnofsky eastern cooperative ecog performance group oncology status kps greater
+Cluster 267: gog performance gynecologic status group oncology patients grade patient protocol
+Cluster 268: performance ecog status ps patients step registration score criteria greater
+Cluster 269: cooperative eastern ecog group oncology performance status ps patients score
+Cluster 270: recist measurable response criteria solid evaluation disease tumors evaluable defined
+Cluster 271: measurable disease ct recist patients imaging tomography mri assessed resonance
+Cluster 272: evaluable measurable disease patients parts radiologically recist ca participants clinically
+Cluster 273: feeding breast women pregnant females eligible lactating study girls menarchal
+Cluster 274: allografts organ patients zubrod experimental expert expiratory explained exploratory exposed
+Cluster 275: sun exposure sunscreen protection excessive anticipated avoid willingness adequate use
+Cluster 276: lactating breastfeed females plan infants eligible excluded exposure expert expiratory
+Cluster 277: breastfeed lactating agreed infants unless females eligible female pregnancy potential
+Cluster 278: study pregnant contraception agree participation adequate duration men women use
+Cluster 279: forms medically willing sexually acceptable able contraception childbearing women men
+Cluster 280: bisphosphonate hypercalcemia osteoporosis reasons taking therapy use metastasis symptomatic allowed
+Cluster 281: prohibited use bisphosphonates herbal concurrent dhea ephedra ginseng dehydroepiandrosterone yohimbe
+Cluster 282: wocbp women contraception nivolumab potential men postmenopausal childbearing use instructed
+Cluster 283: women childbearing potential contraception adequate employ unwilling practice male men
+Cluster 284: major procedure surgical anticipation traumatic injury course days biopsy need
+Cluster 285: phase study weeks administered levels referred eligibility early recovered prior
+Cluster 286: major surgery days registration prior delayed immunotherapy toxicity treatment extensive
+Cluster 287: weeks prior therapy study completed radiation shorter recovered half toxicity
+Cluster 288: surgery major weeks recovered prior effects patients placement surgical study
+Cluster 289: investigational receiving agents patients ineligible participants study treatment trials cancer
+Cluster 290: investigational currently drug receiving eligible patients anticancer therapy ineligible anti
+Cluster 291: currently agents anti receiving cancer eligible patients anticancer platelet study
+Cluster 292: receiving agents eligible corticosteroid currently anti corticosteroids investigational cypa drugs
+Cluster 293: blocks slides tissue notified unavailable sent chair enrollment available study
+Cluster 294: approaching biospecimens department regarding check release investigators submission pathology site
+Cluster 295: tissue tumor biopsy available archival submission slides paraffin patients block
+Cluster 296: investigational agent receiving received treatment days neoplasm type patients dose
+Cluster 297: investigational agents weeks receive past received planning patients receiving anticancer
+Cluster 298: cycle day herbal therapy week weeks prior contraceptives anticancer radiotherapy
+Cluster 299: cycle day investigational agent weeks treatment prior past agents received